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Background: The objective of this study was to estimate the cost-effectiveness of denosumab 
for fracture prevention compared with no treatment, generic bisphosphonates, and strontium 
ranelate in a cohort of osteoporotic postmenopausal women in Spain.
Methods: A Markov model represented the possible health state transitions of Spanish 
postmenopausal women from initiation of fracture prevention treatment until age 100 years 
or death. The perspective was that of the Spanish National Health System. Fracture efficacy 
data for denosumab were taken from a randomized controlled trial. Fracture efficacy data for 
alendronate, ibandronate, risedronate, and strontium ranelate were taken from an independent 
meta-analysis. Data on the incidence of fractures in Spain were either taken from the published 
literature or derived from Swedish data after applying a correction factor based on the reported 
incidence from each country. Resource use in each health state was obtained from the literature, 
or where no data had been published, conservative assumptions were made. Utility values for 
the various fracture health states were taken from published sources. The primary endpoints of 
the model were life-years gained, quality-adjusted life-years (QALYs), and incremental cost-
effectiveness ratios for denosumab against the comparators.
Results: Denosumab reduced the risk of fractures compared with either no treatment or the 
other active interventions, and produced the greatest gains in life-years and QALYs. With an 
annual acquisition cost of €417.34 for denosumab, the incremental cost-effectiveness ratios for 
denosumab versus no treatment, alendronate, risedronate, and ibandronate were estimated at 
€6,823, €16,294, €4,895, and €2,205 per QALY gained, respectively. Denosumab dominated 
strontium ranelate. Sensitivity analyses confirmed the robustness of these findings.
Conclusion: Our analyses show that denosumab is a cost-effective intervention for fracture 
prevention in osteoporotic postmenopausal women in Spain compared with alendronate and 
risedronate, and is a dominant treatment option compared with strontium ranelate.
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Introduction
Osteoporosis is a progressive skeletal disease that commonly occurs in women as they 
age, leading to a reduction in bone mass and quality,1–3 and ultimately increased sus-
ceptibility to bone fractures. It is a disorder associated with significant fracture-related 
morbidity in elderly postmenopausal women, including negative effects on quality of 
life because of chronic pain, depression, and limitations on social activity,4–7 as well as 
increased mortality.8 Estrogen deficiency is one of the main determinants of osteoporosis 
in women after menopause.9 Epidemiology data from Spain suggest a prevalence rate of 
postmenopausal osteoporosis (PMO) of approximately 25% for women aged 60–69 years 
and 40% for those aged 70–79 years.10 As such, PMO places a significant burden on 
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health care resources, particularly owing to the increased risk 
of fractures.11–13 In 2009, it was estimated that the costs of 
osteoporosis in Europe would double from €40 billion in 2000 
to almost €80 billion in 2050.14 The cost related to hospital-
izations due to osteoporotic vertebral fractures in Spain was 
estimated to be €41 million in 2007.15 A more recent estimate 
for osteoporotic hip fractures in Catalonia put the direct costs 
in this region alone at €50 million.16
Pharmacological treatment options for PMO can gener-
ally be classified by their action on bone remodeling as either 
antiresorptive or anabolic agents, with the primary goal of 
treatment being a reduction in fracture risk.17 Antiresorptive 
drugs generally act to reduce bone remodeling, and lower 
fracture risk by preserving the microarchitecture of the skel-
eton and increasing bone mass.18 Antiresorptive drugs such 
as bisphosphonates are established therapies for PMO.8,12,19 
Denosumab is a relatively new antiresorptive agent that 
targets the cytokine system involved in bone turnover regu-
lation (RANKL, a cytokine that is an essential mediator for 
osteoclast formation, function, and survival).20 Denosumab 
is a human monoclonal antibody with high affinity and speci-
ficity for RANKL.21 By binding to and inhibiting RANKL, 
denosumab prevents its interaction with its receptor, RANK, 
on osteoclasts and their precursors, thus inhibiting bone 
resorption. Anabolic treatments, such as teriparatide, have 
been used more recently to stimulate bone formation.11,18,20,22 
In addition, drugs such as strontium ranelate, which work by 
inhibiting the osteoclast and stimulating the osteoblast, have 
been approved for the treatment of PMO in Europe over the 
last few years.20,23
Oral bisphosphonates are well established as effective 
first-line therapies for the management of PMO. However, 
some forms of bisphosphonate therapy can involve poten-
tially inconvenient dosing regimens, including daily/
weekly administration, which may have implications for 
adherence.8,24–28 They may also have adverse effects, such 
as gastrointestinal irritation29 or nephrotoxicity.30,31 These 
and other well-known potential adverse effects may limit 
bisphosphonate use in some women with PMO. Moreover, 
consideration of these adverse events and lack of adher-
ence may influence their overall cost-effectiveness relative 
to other guideline-recommended PMO treatments. The 
Spanish treatment guidelines, issued by the Spanish Society 
of Rheumatology, have recently been updated to reflect new 
developments in the management of PMO, and include two 
new antiresorptive drugs, bazedoxifene and denosumab.32 
However, there is a lack of information comparing the cost-
effectiveness of these newly recommended treatments with 
relevant alternative options that would help better inform 
clinical decision-making in Spain.
The objective of this study was to estimate the cost- 
effectiveness of denosumab for osteoporotic fracture preven-
tion compared with generic bisphosphonates (alendronate, 
ibandronate, risedronate), strontium ranelate, and no treat-
ment in a cohort of postmenopausal Spanish women.
Patients and methods
Model structure
A Markov model (Figure 1) was created to represent the possi-
ble health state transitions of Spanish postmenopausal women 
from initiation of treatment for fracture prevention until age 
100 years or death. The model was developed from a previ-
ously published model used to assess the cost-effectiveness of 
denosumab for the treatment of PMO in different countries.33 
The current analyses were conducted from the perspective of 
the Spanish National Health System.
The model covered a total of eight health states: “well”, 
“wrist fracture”, “vertebral fracture”, “hip fracture”, “other 
osteoporotic fracture”, “post-vertebral fracture”, “post-hip 
fracture”, and “dead”. The cycle length for transition between 
the various health states was 6 months. All patients began in 
the “well” health state. In each cycle, patients could experi-
ence a fracture, remain healthy, or die, and could transition 
between health states.
Wrist fracture
Hip
fracture
Vertebral
fracture
Post-vertebral
fracture
Post-hip
fracture
Dead
Well
Other
osteoporotic
fracture
Figure 1 Markov model used to represent the possible health state transitions of 
spanish women with postmenopausal osteoporosis.
Notes: The analysis time began from the initiation of fracture prevention treatment 
until age 100 years or death. This model was developed from Jonssen et al33 with 
the analyses conducted from the perspective of the spanish national health service. 
springer and the original publisher, Osteoporosis international, volume 22, 2010, 
page 968, Cost-effectiveness of Denosumab for the treatment of postmenopausal 
osteoporosis, B. Jönsson, O. ström, J. a. Eisman, a. Papaioannou, E. s. siris, a. Tosteson, 
J. A. Kanis, figure 1. © International Osteoporosis Foundation and National Osteoporosis 
Foundation 2010. With kind permission from springer science and Business Media.
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If the patient died, they moved to the “dead” health state 
and remained there for the rest of the simulation. If the 
patient incurred a fracture, they moved, depending on frac-
ture type, to either the “hip fracture”, “vertebral fracture”, 
“wrist fracture”, or “other osteoporotic fracture” health states. 
After 1 year in one of these health states, the patient could 
experience a new fracture, or move to the “post-hip fracture”, 
“post-vertebral fracture”, or “dead” health states. Those with 
wrist fractures and other osteoporotic fractures were assumed 
to have had an impact on costs and morbidity in the first year 
after the fracture only, and therefore, after 1 year in these 
health states, these patients moved (assuming no new fracture 
had occurred) back to the “well” health state.
Patients in the post-vertebral fracture state could stay in 
this state, have a vertebral fracture or hip fracture, or die. 
Those in the “post-hip fracture” health state could only stay 
in this health state, have another hip fracture, or die. Conse-
quently, patients who had a hip fracture could not experience 
any future wrist, vertebral, or other osteoporotic fractures, 
and patients in the vertebral and post-vertebral health states 
could not have a wrist fracture, which highlights a limita-
tion of the model. Patients who sustained fractures incurred 
fracture-specific costs and reductions in health utilities.
The risk of sustaining a fracture in the model depends 
on three elements: the risk for an individual in the general 
population of incurring a fracture (specific input by age and 
fracture location based on epidemiology data); the increased 
fracture risk associated with osteoporosis (relative risk [RR]); 
and a risk reduction, if any, attributed to a treatment.
The RR of fracture in patient groups compared with 
the general population risk was calculated from age, bone 
mineral density (BMD), and the prevalence of vertebral 
fractures using previously described methods.34–36 The risk 
contribution from prior vertebral fracture was re-estimated 
for each cycle to account for age-dependent changes in the 
prevalence of vertebral fracture in the general population. 
The RR of hip fractures was also adjusted over time to 
accommodate the decreasing gradient of fracture risk per 
standard deviation of BMD with age.37 RRs at or below a 
certain femoral neck T-score were calculated by dividing 
the distribution below a given T-score into 0.1 standard 
deviation wide slices, and summarizing the RR. This 
method was applied because RR increases exponentially 
with decreasing BMD.
Note that the model estimates consequences of vertebral 
fractures that come to clinical attention whilst the baseline 
risk of the patient population also is based on the prevalence 
of morphometric fractures. This method was used conserva-
tively because morphometric vertebral fractures contribute 
to fracture risk,38 but have unclear consequences for costs 
and quality of life.33
Efficacy and safety
The fracture efficacy data for denosumab were derived from 
FREEDOM (Fracture REduction Evaluation with Deno-
sumab in Osteoporosis every 6 Months), the pivotal trial that 
constituted the basis for approval of denosumab in the USA 
and European Union.39,40 The FREEDOM trial consisted of 
7,868 women with a mean age of 72 years. The mean BMD 
T-scores were −2.8 at the lumbar spine, −1.9 at the total hip, 
and −2.2 at the femoral neck. Approximately one quarter 
(24%) of the women had a vertebral fracture at baseline. 
Denosumab reduced the fracture risk by 68% (95% confi-
dence interval [CI] 59–74), 40% (95% CI 3–63), 20% (95% 
CI 5–33), and 16% (95% CI −11, 37) for new vertebral, 
hip, non-vertebral, and wrist fractures, respectively.39,40 The 
risk reductions for non-vertebral fractures were used as the 
efficacy values for “other” fractures.
The efficacy data for the other active treatment com-
parators were taken from a meta-analysis conducted by the 
National Institute for Health and Care Excellence.41 The 
efficacy rates for all the comparators included can be seen 
in Table 1.
The FREEDOM study also included prespecified sub-
group analyses of patients at higher risk of fracture, including 
those with a baseline femoral neck BMD T-score −2.5 or 
less.39,42,43 We used the efficacy data in this subpopulation of 
high-risk patients in FREEDOM for sensitivity analyses. As 
no other product had reported data in a similar subpopula-
tion, a conservative approach was taken by not varying the 
efficacy rates for the comparators in sensitivity analyses. For 
the multivariate sensitivity analysis, specific efficacy data for 
denosumab were used for patients older than 75 years. This 
was not done for comparators, again following a conservative 
approach, since risk reductions for this specific population 
were either not reported or lower than that in the overall 
population (Table 1).
Adverse events associated with osteoporosis medications, 
including denosumab, are usually mild and transient.40,44,45 
The cost and quality of life impact of adverse events would 
be minor and they were not included in the analysis as in 
other studies.46
Fracture incidence and mortality
Data on the incidence of fractures in Spain were taken from 
either the published literature (in the case of hip fractures)47 
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or derived from Swedish data after applying a reduction 
factor based on the reported incidence from both countries 
(Spain compared with Sweden).48–51 These were then linearly 
extrapolated and interpolated with the midpoint values for 
a range of ages used (eg, age 52 years in the 50–54-year 
age group). Patients with hip or vertebral fractures have an 
increased mortality risk compared with the general popula-
tion.52,53 Wrist fractures are not associated with increased 
mortality at any age. Increased mortality risks due to hip or 
vertebral fracture were applied, from published sources,52,53 to 
the Spanish mortality rate for women based on 2009 data.54 
The RR of death, in the case of hip and vertebral fractures, 
declines with age, and this was factored into the model. 
A study on the RR of death from “other fractures” showed 
that the variation in fracture risk did not vary greatly by age,55 
so the RR of death remained as a constant for all ages in our 
model. Evidence suggests that much of the excess mortality 
associated with osteoporosis is not actually a function of the 
fracture,53,56 but perhaps of the generally more frail condition 
of patients with osteoporosis. As such, the RRs of death after 
fracture were adjusted for comorbidities, and the duration 
of the increased mortality used in the model was 8 years, 
which was the follow-up period of the two studies used here 
to estimate comorbidity.48,51
The population incidence and risk of fractures by type and 
age, and the RR of mortality linked to the different fracture 
types and age, can be seen in Table 2. The RRs resulting from 
the model for sustaining a fracture at the hip, spine, wrist, or 
“other sites” for the base-case population (T-score #2.5 or 
less, started treatment at age 65 years, and 28% prevalence of 
osteoporotic fracture) compared with the overall population 
were 4.36, 3.20, 1.68, and 2.00, respectively. This confirms 
the higher risk of fracture of the base-case population com-
pared with the overall population.
Resource use and costs
Resource use and resource unit cost were collected separately. 
The resource use in each health state was obtained from the 
literature where possible, and, for those where no data had 
been published, conservative assumptions were made as to 
the probable level of resource consumption. Data obtained 
from the literature included hospital admissions, nursing 
home costs, and drug treatments for osteoporosis. The costs 
of resources used were taken from published sources, indi-
vidual hospitals, or nationally available data sources such 
as eSalud57 and BOT Plus (Portalfarma, Consejo Oficial de 
Colegios Oficiales de Farmacéuticos),58 and were inflated 
to 2013 prices using the Spanish Consumer Price Index T
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where appropriate (not for drug costs). Certain assumptions 
were also made in the absence of published information: all 
interventions were associated with a single physician visit 
per year, as part of the standard monitoring of treatment. 
In addition, denosumab was associated with the cost of one 
nurse visit per year due to its 6-month subcutaneous injection 
cycle (assuming that 50% of all doses in a year were either 
self-administered, administered by a relative, or administered 
during annual physician visits) and there were no differences 
in tests or analyses due to the treatment administered.
In the base-case analysis, it was assumed that only 
hip fractures would potentially incur long-term care costs 
(associated with residence in nursing homes). The probability 
of requiring a nursing home was conservatively assumed 
to be 15% based on two previously published Spanish 
studies.59,60
The other types of fractures (wrist, vertebral, and others) 
were associated only with costs at the time of the event. 
Both costs and benefits were discounted at 3% in the base 
case in line with current best practice in Spain.61 The costs 
included in the analyses are reported in Table 3. The retail 
price of denosumab and the comparator treatments were 
used, including a mandatory 7.5% reduction in the cases of 
strontium ranelate and denosumab, as mandated for branded 
drugs in Spain.58
Utilities
Utility values, which represent the reduction in quality of 
life, for the various fracture health states were taken from 
published sources.62,63 The five-dimension European quality 
of life questionnaire values for the general population in 
Spain were taken from a recent publication.38 These values 
are shown in Table 4. It was assumed that only hip and ver-
tebral fractures would have associated disutility beyond the 
first year post-fracture.
Persistence
Several economic analyses previously undertaken have 
failed to consider persistence with treatment, which 
reduces their usefulness to decision-makers.64 The pre-
sented model analyses explicitly included treatment per-
sistence and its impact on predicted treatment costs and 
health outcomes. In the model, persistence was defined 
as the length of time that the medication was taken by 
the patient. Persistence rates for denosumab treatment 
were based on the DAPS (Denosumab Adherence Prefer-
ence Satisfaction) study,62 a randomized crossover study 
Table 2 Fracture incidence and mortality at selected ages
Age  
(years)
Risk of fracture Risk of mortality compared with population norms
Hip Vertebral Wrist Other Hip  
(year 1)
Vertebral 
(year 1)
Hip  
(year 2+)
Vertebral 
(year 2+)
Other 
(year 1)
50 0.00025 0.00124 0.00225 0.00304 9.79 12.07 3.62 7.94 1.22
55 0.00023 0.00121 0.00247 0.00370 8.64 10.15 3.34 6.67 1.22
60 0.00054 0.00187 0.00293 0.00392 7.69 9.04 3.11 5.94 1.22
65 0.00104 0.00293 0.00359 0.00663 6.39 7.43 2.70 4.88 1.22
70 0.00221 0.00490 0.00459 0.00948 5.54 5.98 2.44 3.93 1.22
75 0.00496 0.00745 0.00549 0.01553 4.16 4.39 1.91 2.88 1.22
80 0.00996 0.00870 0.00637 0.02268 2.92 2.75 1.39 1.81 1.22
85 0.01817 0.01105 0.00737 0.03800 2.15 1.98 1.06 1.30 1.22
90 0.02543 0.01469 0.00837 0.05955 1.63 1.36 1.00 1.00 1.22
Table 3 Costs (2013 prices)
Cost (€)
Age group (years)
50–64 65–74 75–84 $85
Fracture site95
 hip 10,236 11,931 12,684 18,841
 Vertebral 3,994 13,683 13,683 13,683
 Wrist 1,981 1,981 1,981 1,981
 Other 1,981 1,981 1,981 1,981
Annual drug costs  
(including all sales taxes)58
Cost (€)
Denosumab 417.34
alendronate 162.82
Risedronate 283.80
ibandronate 156.00
strontium ranelate 595.54
non-drug costs
  Medical costs associated  
with hip fracture (year 2+)95
5,480
  Daily cost of nursing home/ 
long-term care57
86.95
  Cost of a physician visit95 59.18
  Cost of iV administration  
per injection57
209.33
  Cost of a nurse visit57 20.67
Abbreviation: iV, intravenous.
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that compared the persistence on denosumab with that of 
weekly alendronate in a cohort of 250 patients observed 
for 24 months. This study showed that non-persistence in 
the first year (before crossover) was 9.5% for denosumab 
and 20.2% for alendronate, which represents a 50% RR 
reduction in non-persistence with denosumab.65 Persis-
tence rates for the bisphosphonates and strontium ranelate 
were taken from the Swedish Adherence Register Analy-
sis study, which included data on over 56,000 patients 
treated for osteoporosis between 2005 and 2009.66 For the 
comparators, a composite estimate was used rather than 
the persistence rates for individual treatments because it 
was felt that comparator persistence would appear to be 
too low as many patients may simply have switched to 
an alternative treatment. Persistence for denosumab was 
obtained applying the RR reduction obtained in DAPS to 
the composite estimate for comparators. The persistence 
rates used in the model are also presented in Table 4.
In the base-case population, it was assumed that patients 
were at risk of discontinuing treatment during the first 3 years 
only, after which they would remain adherent to their treat-
ment until termination or death.
It has been recognized that treatment effects in osteo-
porosis persist for a length of time even after the treatment 
has stopped (defined as the offset time),67,68 and that this 
can impact cost-effectiveness.69–72 There have been very 
few studies that evaluate offset time. The findings also 
seem inconsistent. For all treatments, the offset time could 
not be determined precisely for fractures. When making 
assumptions for an economic model, differential effects for 
treatments should be based on solid evidence. At this time, 
there is not robust evidence to support differential offsets, 
so we assume that they are equal for all treatments. In the 
absence of more conclusive evidence for differential offset 
time, the offset time used in the base-case analysis was 
assumed to be equivalent to the time spent on treatment up 
to a maximum of 2 years; this was shorter for patients who 
discontinued treatment earlier. Additionally, the treatment 
effect decreased linearly during the offset time. The model 
assumed that the maximum duration of treatment for a fully 
persistent patient would be 5 years; therefore, the maximum 
treatment effect time would be 7 years (comprising 5 years 
of full persistence and 2 years of offset time).
analyses
The primary endpoints of the model were life-years gained, 
quality-adjusted life-years (QALYs), and incremental cost-
effectiveness ratios (ICERs) for denosumab against the 
comparators. Univariate sensitivity analyses were performed 
using efficacy data from the denosumab FREEDOM study 
for a subpopulation of patients with T-scores of –2.5 or less 
at the femoral neck, and by extrapolating the treatment dura-
tion to 10 years. Multivariate analyses were performed using 
several variables simultaneously: age at treatment initiation, 
T-score, and fracture prevalence, comparing denosumab with 
either no treatment or alendronate (as these were seen as the 
most likely alternative options).
Using the base-case model, probabilistic sensitivity 
analyses were conducted using 5,000 simulations. The 
variables selected and included in this analysis were: 
denosumab effects, comparator effects, difference in per-
sistence between denosumab and other treatments (DAPS 
results), and age-dependent costs and utilities for the first 
year (for hip, vertebral, wrist, and others), age-independent 
costs, and utilities for the second and subsequent years (hip 
and vertebral fractures only). Estimates for costs and utilities 
were sampled from a normal distribution and estimates of 
hazard ratios for treatment efficacy and the probability of 
discontinuing treatment were sampled from a log-normal 
distribution.
Table 4 Utility values and treatment persistence
Fracture Utility multiplier
First year only
 hip 0.700
 Vertebral 0.590
 Wrist 0.956
 Other 0.902
subsequent years
 hip 0.800
 Vertebral 0.929
Time since  
initiation (months)
Discontinuation rates (%)
Denosumab Comparators
Persistence rates
 6 18.6 37.2
 12 13.1 26.1
 18 11.2 22.4
 24 9.9 19.8
 30 10.2 20.5
 36 15.2 30.3
Age (years) Mean
EQ-5D mean index values (time trade-off value set)
 18–24 0.981
 25–34 0.970
 35–44 0.942
 45–54 0.919
 55–64 0.894
 65–74 0.857
 $75 0.729
 Total 0.912
Abbreviation: EQ-5D, five-dimension European quality of life questionnaire.
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Input data for the probabilistic sensitivity analyses were 
taken from the relevant input data sources where possible 
(Table 5). Denosumab and comparator effect confidence 
intervals (CIs) were taken from the National Institute for 
Health and Care Excellence appraisal.41 The RR for non-
persistence with denosumab versus other treatments was 
0.5 (95% CI 0.30–1.00).65 In the absence of specific data for 
Spain, standard error proportions of the mean for fracture 
costs were derived from data from Sweden and were based 
on the CIs of the whole samples for the respective fracture 
types.73 The standard error proportions of the mean for hip, 
vertebral, and wrist fractures were 5%, 13%, and 7%, respec-
tively. The value for “other” fractures was assumed to be the 
same as for vertebral fractures, so it was the type with the 
greatest uncertainty.
Utility multiplier CIs from the study by Peasgood et al63 
were used to calculate the standard error of the mean (SEM) 
percentage where applicable. The CIs for hip, vertebral, and 
wrist fractures were 0.64–0.77, 0.46–0.83, and 0.86–1.00, 
respectively, and 0.68–0.96 for year 2 and onwards for hip 
fractures. The standard error proportions of the mean for hip, 
vertebral, and wrist fractures were thus 3%, 6%, and 4%, 
respectively, and 7% for year 2 and onwards for hip fractures. 
“Other” fractures were assumed to have the same SEM 
percentage as vertebral fractures, and the SEM percentage 
for vertebral fractures in year 2 and onwards were assumed 
to be the same as for vertebral fractures in year 1. Lastly, in 
the absence of Spanish data, the SEM percentage for patients 
with hip fractures going into long-term care was derived from 
the study by Zethraeus et al74 and was 5% (Table 5).
Results
Base case
The base case in the model assumed patients had been diag-
nosed with osteoporosis (T-score –2.5 at any site), had a 28% 
prevalence of osteoporotic fracture (reported fracture preva-
lence for patients with T-score #2.5 or less in Spain),75 and 
had started treatment at the age of 65 years. The comparison 
between denosumab, bisphosphonates, strontium ranelate, 
and no treatment in the base-case analysis is presented in 
Table 6.
Denosumab reduced the risk of fractures compared with 
either no treatment or the other active interventions, and 
produced the greatest gains in life-years and QALYs. The 
total cost for denosumab was, however, higher compared with 
the other treatment options, with the exception of strontium 
ranelate. Denosumab dominated strontium ranelate because 
it was both more effective and less costly. With an annual 
acquisition cost of €417.34 for denosumab,58 the ICERs for 
denosumab versus no treatment, alendronate, risedronate, 
and ibandronate were estimated at €6,823, €16,294, €4,895, 
and €2,205 per QALY gained, respectively.
sensitivity analyses
The first sensitivity analysis assessed the impact of using 
efficacy data from the FREEDOM study for the population 
of patients with a T-score of −2.5 or less at the femoral neck 
(ie, those with a high risk of fracture, Table 6). This sensitiv-
ity analysis showed that, compared with the base case, the 
ICER estimates improved as denosumab reduced the fracture 
risk further. Estimated ICERs for denosumab compared with 
no treatment, alendronate, and risedronate were €3,311, 
€9,492, and €132 per QALY gained, respectively. As in the 
Table 5 input distributions for probabilistic sensitivity analysis
Treatment Relative risk of fractures – 
treatment versus placebo
Fracture 
site
Ratio Lower  
CI
Upper 
CI
Denosumab hip 0.60 0.37 0.97
Vertebral 0.32 0.26 0.41
Wrist 0.84 0.63 1.11
Other 0.80 0.67 0.95
alendronate hip 0.62 0.40 0.96
Vertebral 0.56 0.46 0.67
Wrist 0.85 0.67 1.09
Other 0.82 0.73 0.93
Risedronate hip 0.74 0.59 0.93
Vertebral 0.64 0.52 0.78
Wrist 0.68 0.43 1.07
Other 0.80 0.72 0.90
ibandronate hip 1.00 1.00 1.00
Vertebral 0.51 0.34 0.74
Wrist 1.00 1.00 1.00
Other 1.00 1.00 1.00
strontium ranelate hip 0.85 0.61 1.19
Vertebral 0.62 0.55 0.71
Wrist 1.00 0.74 1.36
Other 0.86 0.74 0.99
Fracture type and  
duration
Relative standard errors of the mean
Cost (%) Utilities (%)
hip fracture, year 1 5 3
Vertebral fracture, year 1 13 6
Wrist fracture, year 1 7 4
Other fracture, year 1 13 6
hip fracture, year 2+ 10 7
Vertebral fracture, year 2+ 10 6
Proportion of hip  
fracture patients going  
on to long-term care
Relative standard error of the mean
5%
Abbreviation: CI, confidence interval.
ClinicoEconomics and Outcomes Research 2015:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
112
Darbà et al
Table 7 incremental cost-effectiveness ratios produced in multivariate sensitivity analysis
T-score No previous fracture Previous fracture
Age (years) Age (years)
60 65 70 75 60 65 70 75
Denosumab versus no treatment
  #−2.5 €28,002 €15,185 €1,629 Cost-saving €2,400 Cost-saving Cost-saving Cost-saving
  #−3.0 €16,018 €5,808 Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving
  #−3.5 €5,867 Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving
  #−4.0 Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving
Denosumab versus alendronate
  #−2.5 €42,598 €27,501 €12,772 Cost-saving €9,890 €4,102 Cost-saving Cost-saving
  #−3.0 €28,625 €16,487 €4,132 Cost-saving €3,932 Cost-saving Cost-saving Cost-saving
  #−3.5 €16,840 €7,038 Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving
  #−4.0 €7,173 Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving
Table 6 Results of base case and sensitivity analyses
Total  
costs (€)
Life-years Life-years  
(adjusted)
QALYs ICER (€/QALY): denosumab 
versus comparator
Base case
 no treatment 23,122 20.803 15.156 11.899 6,823
 alendronate 22,980 20.818 15.166 11.920 16,294
 Risedronate 23,298 20.815 15.164 11.915 4,895
 ibandronate 23,388 20.818 15.165 11.914 2,205
 strontium ranelate 23,890 20.815 15.163 11.913 Dominant
 Denosumab 23,467 20.842 15.180 11.950 –
sensitivity analysis (high fracture-risk population [T-score #−2.5 at femoral neck])
 no treatment 23,122 20.803 15.156 11.899 3,311
 alendronate 22,981 20.818 15.166 11.920 9,492
 Risedronate 23,299 20.815 15.164 11.915 132
 ibandronate 23,389 20.818 15.165 11.914 Dominant
 strontium ranelate 23,891 20.815 15.163 11.913 Dominant
 Denosumab 23,304 20.843 15.181 11.954 –
sensitivity analysis (treatment duration extended to 10 years)
 no treatment 23,122 20.803 15.156 11.899 3,817
 alendronate 22,837 20.823 15.168 11.928 11,573
 Risedronate 23,307 20.819 15.166 11.921 2,077
 ibandronate 23,469 20.822 15.168 11.919 Dominant
 strontium ranelate 24,155 20.818 15.166 11.918 Dominant
 Denosumab 26,680 20.862 15.192 11.979 –
Abbreviations: iCER, incremental cost-effectiveness ratio; QalY, quality-adjusted life-year.
base-case analysis, denosumab was a dominant treatment 
alternative to strontium ranelate. It was also shown to be a 
dominant option compared with ibandronate.
The second sensitivity analysis, in which the treatment 
duration was extended to 10 years, showed that denosumab 
was the dominant treatment option compared with iban-
dronate or strontium ranelate. The cost per QALY gained was 
€3,817, €11,573, and €2,077 compared with no treatment, 
alendronate, or risedronate, respectively.
The multivariate sensitivity analysis, which simultane-
ously varied previous fracture status, age, and T-score, 
showed that, compared with no treatment, denosumab was 
cost-saving in most cases (Table 7).
For the results comparing denosumab with alendronate, 
three key variables were identified: age older than 70 years, 
a T-score of −3.5 or less, and previous fracture. Hence, 
denosumab appears as dominant for patients fulfilling at 
least two of these criteria and dominant or cost-effective for 
most patients fulfilling one of these criteria. Denosumab was 
probably not cost-effective for patients aged 60 years 
without a previous fracture and a T-score −3.0 or more 
(Table 7).
Results of the probabilistic sensitivity analyses using 
5,000 simulations on the base case but simultaneously 
varying the three key variables (age, T-score, and previ-
ous fracture status) showed that denosumab had a 57% 
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probability of being cost-effective compared with alendronate 
or no treatment at a willingness-to-pay threshold of €20,000 
per QALY gained. This probability was even greater (74%) if 
the willingness-to-pay threshold was increased to €30,000 per 
QALY gained (Figure 2).
Discussion
Considerable uncertainty exists around the relative cost-
effectiveness of treatments in osteoporosis. In Spain, there 
is no explicitly stated threshold that defines a point at 
which a treatment is deemed to be cost-effective. However, 
De Cock et al76 suggest that a value between €30,000 
and €45,000 per QALY gained is reasonable. As with all 
such thresholds, there are some examples of technologies 
with costs exceeding €30,000 per QALY gained that have 
achieved reimbursement.76,77 Nonetheless, using this gener-
ally accepted threshold, this study shows that denosumab 
is a cost-effective treatment option for the prevention of 
osteoporotic fractures in postmenopausal women in Spain 
compared with alendronate, risedronate, ibandronate, or 
no treatment. Denosumab was the dominant treatment 
option compared with strontium ranelate. These results 
were demonstrated to be robust in the sensitivity analyses 
undertaken.
A review of 18 previous studies of bisphosphonate use 
concluded that these agents were generally cost-effective 
options for the treatment of PMO, but it was difficult to 
determine if any one agent was conclusively economically 
superior to any other.78 A study of oral bisphosphonates in 
Switzerland concluded that they were likely to be cost-saving 
relative to no treatment,79 while a study of tertiary plus 
secondary prevention measures found bisphosphonates to 
be cost-effective compared with secondary prevention alone, 
according to the perspective of the statutory health insurance 
system in Germany.80
One of the most important challenges for decision-makers 
in the treatment of PMO is identifying the population of 
patients for whom the treatment is most cost-effective. Based 
on the results of the multivariate and probabilistic sensitiv-
ity analyses conducted in our study, denosumab appears 
to be cost-effective or cost-saving in most of the scenarios 
in which it was compared with either alendronate or no 
treatment. Furthermore, for patients at high risk of fractures 
(aged over 75 years, with a previous fracture, or a T-score 
of −3.5 or less), denosumab was cost-saving against both 
alternatives in most of the scenarios. In additional analyses 
(results not shown in the paper), where we assumed that 
there was 100% persistence with the treatments, an identi-
cal pattern was observed compared with no treatment, and 
denosumab was cost-saving in almost all cases. However, the 
results for denosumab compared with alendronate differed, 
with ICERs ranging from €25,046 to €98,776 for patients 
younger than 75 years and with no previous fracture, and 
from €6,918 to €35,427 for patients younger than 75 years 
with a previous fracture. It is noteworthy that for patients 
older than 75 years, denosumab still appears to be cost-saving 
compared with alendronate, both in patients with and without 
previous fracture. However, such complete persistence, as 
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Figure 2 Results of the probabilistic sensitivity analysis showing willingness to pay per quality-adjusted life-year.
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assumed in our model, is rarely seen, so these higher figures 
should be treated with caution.
Generally, previously published studies have tended to 
focus on only one or two active comparators per study. For 
example, a Markov model of the cost utility of risedronate 
in the UK suggested a cost per QALY gained of £8,625 
per treated woman over a 3-year time period relative to no 
treatment. In this case, risedronate was found to be cost-
saving over an expected lifetime.81 Risedronate was also cost-
saving compared with ibandronate in Italy.82 Unfortunately, 
these approaches are of limited utility to decision-makers, 
who are generally faced with a much wider range of treat-
ment options to choose from.
There have also been relatively few attempts to examine 
the cost-effectiveness of osteoporosis treatment in a Spanish 
setting. A study in Spain showed that the incremental cost per 
QALY gained for risedronate compared with no treatment 
in a 70-year-old woman at the “threshold of osteoporosis” 
(defined as a T-score of −2.5) was €32,515.83 A similar analy-
sis of similar patients using the Fracture Risk Assessment 
Tool (FRAX®) reported an ICER of €105,450 with baze-
doxifene compared with placebo,84 and found bazedoxifene 
to be dominant compared with raloxifene.85 A comparison 
of risedronate with alendronate in Spain produced estimates 
of €43,601 to €61,064 per QALY gained for risedronate, 
and €49,483 to €88,634 for alendronate in patients with 
and without vertebral fractures, respectively.86 The authors 
concluded that risedronate was more cost-effective than 
alendronate. A  large-scale, nine-country study published 
by Strom et al using 2004 costs showed that, compared with 
no treatment, the cost-effectiveness of alendronate in Span-
ish patients with at least one previous vertebral fracture was 
€13,193 per QALY gained, and €32,943 per QALY gained 
in patients with no previous fracture history.34 The results 
from our analysis show considerably lower cost per QALY 
estimates for denosumab, which reflects the effect of the 
superior efficacy and persistence relative to other treatments, 
although the results of the studies discussed could have been 
influenced by the use and cost of the branded formulations 
of bisphosphonates rather than the generic versions which 
are now available.
The results of our analysis are broadly consistent with other 
similar attempts to establish the cost-effectiveness of deno-
sumab in various countries. A previous cost-effectiveness 
analysis of denosumab in Greece showed that the incre-
mental cost per QALY gained ranged between €11,114 
and €24,784 compared with no treatment, alendronate, 
ibandronate, risedronate, or strontium ranelate.87 A study 
in Portugal found denosumab to be cost-effective compared 
with alendronate-cholecalciferol, with an ICER of €14,487.88 
In the USA, the ICER for denosumab was $28,300 per 
QALY gained compared with generic alendronate, and 
dominated the other treatment options (risedronate and 
ibandronate),89 depending on the populations considered in 
the analyses. Similar results have been shown in Belgium,46 
Canada,90 and Sweden33 and confirmed by a recent review.45 
While such similarities in outcomes are not surprising, 
given the same basic modeling approach in each case, it is 
notable that the cost-effectiveness estimates, which might 
be expected to be influenced by local pricing and differences 
in health care systems, are within the range of values for 
the ICERs in Spain.
The presented model analyses incorporated persistence 
with treatment as crucial input for the prediction of cost and 
outcomes. This is often missing in osteoporosis models and 
cost-effectiveness models in general.64 The base case also 
included a population with a relatively low fracture risk, 
rather than patients with established osteoporosis, which was 
modeled more closely in the sensitivity analysis. Therefore, 
it is likely that our estimates of the potential benefits and 
cost-effectiveness of denosumab are conservative. There 
are also some limitations to our approach. In the absence of 
Spanish-specific data, we relied on estimates and data from 
other countries to provide some of the inputs into the model. 
In light of differences in cultures and health care systems, 
this undoubtedly increases the uncertainty in our results. 
However, rigorous testing in the sensitivity analyses of these 
assumptions confirmed the robustness of the base-case data. 
The results of the analyses improve with increased treatment 
duration, with the results from the 10-year treatment dura-
tion better than those from 5 years. This could be relevant 
as the long-term efficacy and safety of denosumab has been 
confirmed in a recent review91 and safety data from 8 years 
of denosumab use in the extension to the FREEDOM study 
have recently been presented.92
Conclusion
To our knowledge, this is the first comprehensive attempt to 
model the cost-effectiveness of the most widely used agents 
for PMO in Spain. This is an area of increasing interest to 
both physicians and health care decision-makers, who are 
seeking to determine the best available treatment options 
from a large range of available therapies. Previous modeling 
attempts in Spain have tended to focus on only one or two 
drugs and as such, have only provided limited guidance for 
clinical decision-making. The results of our analyses show 
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that denosumab is a cost-effective intervention for fracture 
prevention in postmenopausal women in Spain compared 
with alendronate, risedronate, ibandronate, or no treatment, 
and is a dominant treatment option compared with strontium 
ranelate. Additionally, for those patients at the highest risk 
of fractures (aged over 75 years, with a previous fracture, or 
a T-score of −3.5 or less), denosumab was generally cost-
saving compared with either alendronate or no treatment in 
most of the scenarios.
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